Add time:08/25/2019         Source:sciencedirect.com

1.1. We investigated the effect of Efonidipine Hydrochloride (cas 111011-79-1) (NZ-105) against acute renal failure (ARF) in male Wistar rats. ARF was produced by ischemia or glycerol.2.2. Ischemia-induced ARF was produced by right nephrectomy and clamping of the left renal artery for 60 min, followed by reperfusion. NZ-105 (20 mg/kg) was orally administered twice a day for 3 days before ARF. The plasma creatinine and urea nitrogen concentrations were markedly elevated in the ischemia ARF group on the 1st day, but the elevation was significantly suppressed by NZ-105 treatment.3.3. Glycerol-induced ARF was produced by intramuscular injection of 50% (v/v) glycerol (10 ml/kg) in rats which were restricted to drinking water for 24 hr. NZ-105 (20 mg/kg) was orally administered twice a day for 3 days before ARF. NZ-105 significantly attenuated the severe impairment of creatinine and urea nitrogen clearances and the elevated fractional sodium excretion (FENa) caused by ARF.4.4. In the kidney homogenate, NZ-105 (10−6−10−4 M) inhibited lipid peroxidation induced by ascorbic acid and Fe or by NADPH and the inhibitory effect of NZ-105 was stronger than α-tocopherol, an antioxidant agent. NZ-105 (10−5−10−3 M) showed radical scavenging action against diphenyl-p-picrylhydrazyl and galvinoxyl induced radicals.5.5. These findings suggest that NZ-105 prevents the renal damage caused by the two kinds of ARF. Moreover, the inhibitory effects of NZ-105 against lipid peroxidation and radical formation may be one of the mechanisms involved in the prevention of ARF.

We also recommend Trading Suppliers and Manufacturers of Efonidipine Hydrochloride (cas 111011-79-1). Pls Click Website Link as below: cas 111011-79-1 suppliers